Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2020-11-03 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
独立董事公开征集委托投票权报告书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as an "Independent Director Public Solicitation of Proxy Voting Rights Report" related to a specific shareholders' meeting (the 2020 fifth extraordinary general meeting) of Yunnan Walvax Biotechnology Co., Ltd. It details the solicitation of proxy votes by an independent director for specific proposals concerning a 2020 stock option incentive plan. The document includes legal disclaimers referencing the China Securities Regulatory Commission, detailed instructions for shareholders on how to submit proxy votes, and an attached proxy authorization form. There are no financial statements, earnings data, or management discussion of financial results. The document is a formal report related to the solicitation of voting rights for a shareholder meeting, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). However, since it is a solicitation report prior to the vote, it is more precisely a proxy solicitation or voting rights announcement. Given the detailed nature and the focus on proxy voting rights solicitation, the best fit is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (5172 characters) and content confirm it is not a brief announcement or a simple notice but a full report on proxy solicitation. Therefore, the classification is DVA with high confidence.
2020-11-03 Chinese
关于公司2020年股票期权激励计划披露的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (943 characters) regarding the company's 2020 stock option incentive plan. It includes details about the plan, the number of stock options to be granted, the types of recipients, and the need for shareholder approval at an upcoming extraordinary general meeting. It does not contain detailed financial statements or comprehensive report data. The document also references that the full announcement is available on the official disclosure website. Given the short length and nature of the content, this is an announcement related to capital/financing activities (stock option incentive plan) rather than a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-11-03 Chinese
关于放弃惠生（中国）投资有限公司拟转让的上海泽润生物科技有限公司股权优先购买权的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding its decision to waive the preemptive rights to purchase shares being transferred by another shareholder in a subsidiary company. It details the transaction overview, parties involved, shareholding changes, and impact on the company. There are no financial statements or detailed financial performance data presented. The document is a formal disclosure about a capital transaction involving share transfer rights and ownership structure changes. This fits the category of Capital/Financing Update (CAP), as it relates to changes in capital structure and shareholding but is not a full financial report or earnings release.
2020-11-03 Chinese
第四届监事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 11th meeting of the 4th Supervisory Board of Yunnan Watson Biotechnology Co., Ltd. It details the approval of a 2020 stock option incentive plan, its implementation assessment methods, and the list of incentive recipients. The document includes voting results and references to further details on a regulatory disclosure website. It is a corporate governance-related announcement about supervisory board decisions and internal approvals rather than a full report or financial statement. It does not contain financial data or detailed management discussion but focuses on governance and supervisory board resolutions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2020-11-03 Chinese
第四届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 14th meeting of the 4th Board of Directors of Yunnan Watson Biotechnology Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references to further documents on the stock option incentive plan and other corporate governance matters. The content focuses on board decisions and approvals, including stock option plans and authorizations to the board, which are typical subjects of board/management information disclosures. There is no detailed financial data, earnings information, or full report content. The document is not a report itself but an announcement of board meeting resolutions. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters, but it contains substantive board meeting content rather than a mere report publication announcement or regulatory filing. Hence, MANG is the best fit with high confidence.
2020-11-03 Chinese
关于子公司收到发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about its subsidiary receiving an invention patent certificate issued by the Chinese National Intellectual Property Administration. It contains no financial data, no discussion of financial results, no regulatory certifications, no voting results, no management changes, no capital or financing updates, and no legal proceedings. The document is brief (659 characters) and serves as a notification of a patent grant, which is a regulatory announcement related to intellectual property. It does not fit into any specific financial report category but is a general regulatory announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-11-03 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.